Please assess the completion status of the following clinical trial:

Trial Title: Singulair(R) In Asthma And Allergic Rhinitis (0476-383)

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Patient is a user of Inhaled Corticosteroid (ICS) or ICS/Long-Acting Beta 2-Agonist (ICS/LABA) at any dosage~* Peak expiratory flow is \> or = 80% of predicted value on the day of visit 1~* Uncontrolled as per Canadian asthma consensus guidelines~Exclusion Criteria:~* Unwilling to stop regular use of histamine H1 antagonists for allergic rhinitis symptoms~* Unwilling to stop use of antihistamine eye drops or cromoglycate eye drops or ophthalmic corticosteroid

- Gender: ALL
- Minimum Age: 15 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- 1 (Type: EXPERIMENTAL): montelukast sodium

Based on this trial design, predict the completion outcome and termination type (if applicable).